Go to the list of all blogs
Bort Wilson's Avatar
published in Blogs
Sep 26, 2026
SCHM vs SPMD: Weighing Two Low-Cost Mid-Cap ETFs

SCHM vs SPMD: Weighing Two Low-Cost Mid-Cap ETFs

Key Takeaways

  • Both SCHM and SPMD are low-cost passive ETFs providing exposure to U.S. mid-cap equities, with identical expense ratios of 0.03%.
  • SCHM tracks the Dow Jones U.S. Mid-Cap Total Stock Market Index with approximately 499 holdings, offering slightly broader diversification than SPMD, which follows the S&P MidCap 400 Index with around 402 holdings.
  • Sector allocations for both funds are concentrated in industrials, information technology, and financials, reflecting standard mid-cap blend characteristics with comparable risk profiles.
  • Top holdings in each ETF represent a modest percentage of assets, emphasizing diversified exposure rather than concentration in a few names.
  • Both funds employ physical replication and quarterly rebalancing aligned with their respective indices, resulting in low turnover and efficient tracking.
  • In the current mid-cap environment, structural similarities suggest investors may differentiate based on index methodology preferences rather than cost or liquidity.

Why These Two Mid-Cap ETFs Stand Out

Schwab U.S. Mid-Cap ETF (SCHM) and SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) compete directly as core holdings for investors seeking U.S. mid-cap equity exposure. Both ETFs target the middle segment of the market capitalization spectrum, where companies often exhibit growth potential combined with established operations. In the prevailing market environment characterized by sector rotation and interest rate dynamics, these funds offer investors alternative index methodologies for accessing similar segments of the equity market. I also checked this using Tickeron’s AI Screener to see how the holdings line up across peers.

Schwab U.S. Mid-Cap ETF (SCHM) at a Glance

The Schwab U.S. Mid-Cap ETF (SCHM) is a passively managed fund that seeks to track the Dow Jones U.S. Mid-Cap Total Stock Market Index. This index comprises approximately 499 mid-cap stocks ranked by market capitalization within the broader U.S. total stock market universe. The ETF maintains a diversified portfolio with top holdings typically accounting for less than 15% of assets combined, spanning sectors such as industrials and information technology. Its expense ratio stands at 0.03%, and it employs physical replication with periodic rebalancing to match index changes. Distinguishing features include broad mid-cap coverage that excludes most large- and small-cap constituents. From what I see, the wider holdings set gives it a slight edge in diversification.

SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) at a Glance

The SPDR Portfolio S&P 400 Mid Cap ETF (SPMD) is a passively managed fund designed to track the S&P MidCap 400 Index. This benchmark includes approximately 402 mid-cap companies selected for their market capitalization, liquidity, and financial viability. The ETF features a concentrated yet diversified set of holdings, with top positions representing a modest share of the portfolio across industrials, financials, and technology sectors. It carries an expense ratio of 0.03% and uses physical replication with rebalancing aligned to index reconstitutions. Key characteristics include a focus on established mid-cap firms meeting specific inclusion criteria. One thing that stands out is how strictly the index applies its selection standards.

The Broader Mid-Cap Landscape

The U.S. mid-cap segment operates within a broader equity market influenced by macroeconomic factors including interest rate expectations, corporate earnings cycles, and sector rotation between growth and value styles. Regulatory developments in areas such as technology and healthcare, along with capital flows into domestic equities, continue to shape the environment. Both ETFs benefit from the mid-cap universe's balance of scale and agility, though they remain exposed to risks such as economic slowdowns affecting smaller-to-mid-sized companies and shifts in investor sentiment toward large-cap dominance. I’m watching this closely as rate decisions unfold.

How the Two Funds Compare in Practice

In recent market cycles, both SCHM and SPMD have demonstrated comparable volatility consistent with mid-cap benchmarks. Relative positioning has varied modestly with index composition differences, as SCHM captures a wider array of mid-cap names while SPMD adheres to stricter selection standards. Performance dynamics tie to broader themes such as industrial sector strength and technology adoption, with neither fund exhibiting significant structural advantages in liquidity or tracking efficiency over extended periods.

Exploring Tickeron’s AI Tools for ETF Research

In my own analysis, I often turn to Tickeron’s AI Screener when comparing funds like these. It lets me quickly filter mid-cap ETFs by holdings count, expense ratios, sector weights, and AI-driven signals, helping confirm that both SCHM and SPMD remain competitive on cost and diversification. The tool’s customizable scans make it straightforward to spot subtle differences in index methodology without manual number crunching. I’ve found it especially useful for staying on top of how these ETFs align with broader market themes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SCHM, SPMD

Contributor

Bort Wilson's AvatarBort Wilson|Beginner

With a background in economics and swing trading, I write about market trends, technical setups, momentum, and opportunities that develop over several days or weeks. I combine economic perspective with practical trading experience to explain why stocks move, what trends may be developing, and which market signals are worth watching.


SCHM in downward trend: 10-day moving average moved below 50-day moving average on September 04, 2026

The 10-day moving average for SCHM crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

SCHM moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCHM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

The Aroon Indicator for SCHM entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SCHM's RSI Indicator exited the oversold zone, 25 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 52 cases where SCHM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

Following a +1.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCHM advanced for three days, in 275 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

SCHM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Notable companies

The most notable companies in this group are Okta (NASDAQ:OKTA), Incyte Corp (NASDAQ:INCY), Guardant Health (NASDAQ:GH), Roku (NASDAQ:ROKU), Nutanix (NASDAQ:NTNX), Tyson Foods (NYSE:TSN), Lattice Semiconductor Corp (NASDAQ:LSCC), CF Industries Holding (NYSE:CF), C.H. Robinson Worldwide (NASDAQ:CHRW), MasTec (NYSE:MTZ).

Industry description

The investment seeks to track as closely as possible, before fees and expenses, the total return of the Dow Jones U.S. Mid-Cap Total Stock Market Index. The index includes the mid-cap portion of the Dow Jones U.S. Total Stock Market Index actually available to investors in the marketplace. The Dow Jones U.S. Mid-Cap Total Stock Market Index includes the components ranked 501-1000 by full market capitalization. The index is a float-adjusted market capitalization weighted index. The fund will invest at least 90% of its net assets in securities included in the index.

Market Cap

The average market capitalization across the Schwab U.S. Mid-Cap ETF (SCHM) ETF is 13.01B. The market cap for tickers in the group ranges from 3.55B to 46.74B. CBRS holds the highest valuation in this group at 46.74B. The lowest valued company is BILL at 3.55B.

High and low price notable news

The average weekly price growth across all stocks in the Schwab U.S. Mid-Cap ETF (SCHM) ETF was 38%. For the same ETF, the average monthly price growth was 58%, and the average quarterly price growth was 353%. IBRX experienced the highest price growth at 22%, while CBRS experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Schwab U.S. Mid-Cap ETF (SCHM) ETF was 7%. For the same stocks of the ETF, the average monthly volume growth was 3% and the average quarterly volume growth was -14%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 53
Price Growth Rating: 54
SMR Rating: 59
Profit Risk Rating: 71
Seasonality Score: 33 (-100 ... +100)
View a ticker or compare two or three
SCHM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category MidCapBlend

Category
Mid-Cap Blend
Address
Schwab Strategic Trust101 Montgomery StreetSan Francisco
Phone
1-800-435-4000
Web
www.csimfunds.com.
Interact to see
Advertisement
AMZN stock declined approximately -4% over the past 30 days amid concerns over elevated AI-driven capital expenditures pressuring margins. Over the past quarter, the stock fell around -13%, reflecting post-earnings selloff and broader tech sector volatility. Major drivers include surging AWS demand offset by high capex forecasts of up to $200 billion for 2026, macroeconomic pressures like trade policy risks, and geopolitical tensions impacting sentiment.
APA Corporation delivered strong Q4 2025 results, beating EPS estimates with $0.91 adjusted earnings per share and $1.0 billion full-year free cash flow. Stock surged over 45% in recent weeks amid rising oil prices and geopolitical tensions, hitting 52-week highs near $45.66. 2026 capital plan set at $2.1 billion, targeting cost savings run-rate of $450 million and flat U.S. oil production.
I've been watching DVN closely in recent sessions, and it's held up well amid a broader energy sector rally driven by elevated oil prices. The stock has outperformed broader indices, which speaks to investor confidence in its strong positioning in U.S. shale plays, especially the Permian Basin. Volatility remains a factor with macroeconomic pressures and commodity swings, but the company's emphasis on capital discipline and returns to shareholders has encouraged steady buying. Trading volumes have increased, indicating growing interest as DVN manages merger developments and production shifts in this market cycle.
LLY stock declined -13% over the past 30 days amid concerns over obesity drug pricing pressures and competition from NVO. Over the past quarter, the stock fell around -17%, despite strong Q4 2025 earnings driven by Mounjaro and Zepbound volume growth. Bearish analyst notes on market saturation and potential price wars outweighed positive trial data for next-gen drugs like retatrutide.
I've been keeping a close eye on EOG Resources (EOG), and it's clear the stock has held up well through recent volatility. Year-to-date gains are approaching 38%, which stands out against the broader energy sector. The shares are trading above key moving averages, supported by investor confidence in the company's low-cost production and diversified multi-basin portfolio. Elevated crude oil prices have provided a tailwind, even as macroeconomic pressures have led to occasional dips. With a solid balance sheet and reliable free cash flow, EOG looks well-positioned in this market cycle.
Diamondback Energy (FANG), a leading independent oil and natural gas producer focused on the Permian Basin, has shown impressive resilience lately. In my view, the stock's climb of around 16% over recent weeks stands out, especially as it has traded near its 52-week high while outperforming key energy indices and the broader market. This momentum seems driven by favorable oil price dynamics, positive analyst revisions, and the company's operational efficiency paired with its exposure to rising crude benchmarks. Even with broader market fluctuations, FANG's robust cash flows and recent dividend enhancements continue to draw interest from both momentum traders and long-term investors.
MTDR stock surged +20% over the past 30 days, driven by escalating oil prices amid Iran conflict disruptions and strong Q4 2025 earnings beat. Over the past quarter, shares climbed +53%, fueled by record production, positive 2026 guidance, and analyst price target upgrades.
I've been watching OXY closely, and it's clear the stock has shown robust strength in recent trading sessions. It's advanced amid heightened oil prices driven by global supply concerns, outperforming broader indices. This reflects investor confidence in its Permian Basin dominance and operational resilience. Trading near the upper end of its 52-week range, OXY benefits from elevated crude realizations that enhance margins in its core upstream business. While sector peers have also gained, the company's focus on cost efficiencies and debt reduction positions it favorably in the latest market cycle. Heightened volume underscores sustained interest as macroeconomic pressures test energy equities.
I've been watching Antero Resources (AR) closely through recent trading sessions, where the stock has handled volatility well amid natural gas price swings and broader energy sector shifts. It's trading near the upper end of its 52-week range, with year-to-date gains exceeding +25%. From what I see, this reflects investor confidence in the company's growing Marcellus footprint and its disciplined approach to capital allocation. The upward momentum ties directly to positive analyst revisions and a solid production outlook. Macro factors like LNG export demand and data center growth continue to support sentiment in the natural gas space.
I've been tracking Magnolia Oil & Gas (MGY) closely, and it's clear the stock has put in a strong showing lately. It's trading near the top of its 52-week range, buoyed by positive dynamics in the energy sector. From what I see, investor interest in oil and gas producers like MGY is picking up, thanks to improved production efficiency and a focus on capital discipline. The shares have held up well, with a PE ratio around 18 and a dividend yield close to 2%. Sector-wide support from stronger commodity prices has helped drive this momentum, placing MGY in a solid spot among exploration and production peers. Trading volume reflects this engagement, aligning with the broader uptick in activity.
PR stock surged +18% over the past 30 days, driven by investment-grade credit rating upgrades from S&P and Fitch, analyst price target increases, and rising oil prices. Over the past quarter, shares climbed +55%, fueled by record Q4 2025 production, strong earnings beat, dividend hike, and robust operational efficiencies. Key factors include credit upgrades enhancing financial flexibility, positive analyst sentiment with multiple buy ratings, and favorable sector trends from higher crude oil realizations.
RRC stock rose +11% over the past 30 days, driven by strong Q4 2025 earnings beat, dividend hike, and positive 2026 guidance. Over the past quarter, shares gained +31%, reflecting robust free cash flow generation and operational efficiency in the Appalachian Basin.
From what I see, Exxon Mobil Corporation (XOM) stands out as one of the world's largest integrated energy companies, involved in the exploration, production, refining, and marketing of oil, natural gas, and petrochemicals. Its business model covers the full hydrocarbon value chain, from upstream production to downstream refining and chemicals, which offers diversification against commodity price swings. In the oil and gas industry, Exxon Mobil maintains a leading position thanks to its vast reserves, especially in high-return areas like the Permian Basin in the U.S. and offshore Guyana. The company's strong fundamentals—record production volumes and ongoing cost savings—have supported recent stock strength, as higher oil prices boost upstream earnings and refining profits from wider margins.
I've been watching TMV closely through recent trading sessions, where it's handled heightened volatility linked to swings in long-term Treasury yields. This ETF delivers -3x the inverse daily performance of 20+ year U.S. Treasuries, and it's held up well amid pressures in the broader fixed income space. From what I see, rising energy costs and macroeconomic uncertainties have driven yields higher, which plays right into TMV's strengths. The fund is trading within its 52-week range, backed by strong liquidity and substantial daily volume—making it suitable for active traders looking to position around rate-sensitive moves. Recent market cycles really underscore TMV's value in tactical strategies tied to bond market shifts.
From what I see, Constellation Energy stands out as the largest producer of carbon-free energy in the U.S., with the nation's biggest nuclear fleet boasting over 21 GW of capacity—that's roughly 10% of U.S. clean energy output. This scale delivers unmatched reliability for baseload power, which is exactly what hyperscalers like Microsoft and Meta need for their 24/7 carbon-free electricity demands to power AI data centers. Post-Calpine acquisition, the company's ~55 GW fleet now spans nuclear, natural gas, and renewables, providing geographic diversity across key markets like PJM and ERCOT.
In my view, Karman Holdings Inc. (KRMN) really stands out in the aerospace and defense sector with its focus on mission-critical subsystems, including payload protection and deployment systems, aerodynamic interstage systems, and propulsion systems. The company serves high-growth markets like hypersonics, strategic missile defense, tactical missiles, and space launch, benefiting from proprietary engineering and manufacturing capabilities that enable rapid development for prime contractors.
As one of the top three global players in the semiconductor memory market, Micron Technology holds about 22% share in DRAM and is building a stronger foothold in NAND flash storage. What stands out to me is the company's leadership in high-bandwidth memory (HBM), which is essential for AI accelerators. By early 2026, Micron has secured around 21% market share here, thanks to its efficient 12-high and 36GB HBM4 stacks that use 30% less power than competitors.
I've been following Viridian Therapeutics ($VRDN) closely as it carves out a strong position in the thyroid eye disease (TED) market—a rare autoimmune disorder that causes orbital inflammation, proptosis, diplopia, and even vision loss in severe cases. The company draws on its antibody discovery and protein engineering expertise to create differentiated IGF-1R inhibitors, building on the validated pathway pioneered by Tepezza (teprotumumab). What stands out to me is how veligrotug diverges from Tepezza's frequent IV infusions: it offers a more convenient 12-week course with robust efficacy demonstrated in Phase 3 trials for both active and chronic TED, which could help it gain market share through better patient tolerability.
I've been following Applied Optoelectronics, Inc. (AAOI) closely as it designs, manufactures, and sells fiber-optic networking products, including optical transceivers, lasers, and components. These serve internet data centers, cable television (CATV), telecom, and fiber-to-the-home (FTTH) markets. What stands out is the company's vertically integrated model—from chip fabrication using proprietary molecular beam epitaxy (MBE) lasers to module assembly—which gives it an edge in rapid innovation and cost control.
I've been following Applied Optoelectronics, Inc. (AAOI) closely as a vertically integrated provider of fiber-optic networking products. The company specializes in lasers, transceivers, and components for internet data centers, cable broadband (CATV), telecom, and fiber-to-the-home (FTTH) markets. What stands out to me is their core competitive edge: in-house manufacturing of semiconductor lasers using Molecular Beam Epitaxy (MBE). This process is superior to the MOCVD method used by many rivals, allowing for higher yields, greater customization, and quicker responses to hyperscaler demands.